News
Decoding 6 Analyst Evaluations For Blueprint Medicines
10 Apr 24
Analyst Ratings
JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target
10 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Needham Reiterates Buy on Blueprint Medicines, Maintains $97 Price Target
26 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy And Safety Data And Advances In Mast Cell Disease Research At 2024 AAAAI Annual Meeting
23 Feb 24
Biotech, News, General
Rigel Pharmaceuticals Acquires U.S. Rights To GAVRETO From Blueprint Medicines; Blueprint Receives $15M Purchase Price; Eligible For Up To $97.5M In Commercial Milestone Payments And $5M In Future Regulatory Milestone Payments
22 Feb 24
M&A, News
(BPMC) - Analyzing Blueprint Medicines's Short Interest
20 Feb 24
Short Sellers, Short Ideas, Trading Ideas
JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target
16 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
15 Feb 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Earnings Scheduled For February 15, 2024
15 Feb 24
Earnings
Blueprint Medicines's Earnings Outlook
14 Feb 24
Earnings
Cracking The Code: Understanding Analyst Reviews For Blueprint Medicines
13 Feb 24
Analyst Ratings
Press releases
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
11 Apr 24
Press Releases
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Apr 24
Press Releases
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6 Mar 24
News, Contracts, Press Releases
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
23 Feb 24
Press Releases
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
15 Feb 24
Earnings, Press Releases
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 Feb 24
Press Releases
Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
1 Feb 24
Press Releases